Skip to main content

Advertisement

SpringerLink
Log in

Avoidance and Management of Adverse Reactions to Antituberculosis Drugs

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Potent antibiotics are required to cure tuberculosis and reduce the burden of illness in the community. Minor adverse effects are commonly encountered and can be managed by reassurance and explanation. Significant hypersensitivity reactions require cessation of all antituberculosis drugs. Adverse effects should be treated appropriately. An effective antituberculosis regimen should be reestablished as soon as possible. Desensitisation may be necessary if suitable alternative drugs cannot be used. In the event of drug-induced hepatitis, all hepatotoxic drugs should be ceased until symptoms resolve and liver function tests return to normal. Other significant direct toxic effects should be promptly detected and appropriately treated. A thorough knowledge of potential adverse reactions and pharmacokinetics is essential for any physician using antituberculosis drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organisation. Tubercle 1991; 72: 1–6

    PubMed  CAS  Google Scholar 

  2. Fox W. Tuberculosis in India, past, present and future. Indian J Tuberculosis 1990a; 37: 175

    Google Scholar 

  3. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982; 23: 56–74

    PubMed  CAS  Google Scholar 

  4. Pannier R. Drug induced lung disease. Eur J Respir Dis 1983; 64 Suppl. 126: 151–6

    Google Scholar 

  5. IUATLD (International Union Against Tuberculosis and Lung Disease). Antituberculosis regimens of chemotherapy. Recommendation from the committee on treatment of IUALTD. Bull Int Union Tuberc Lung Dis 1988; 63(2): 60–64

    Google Scholar 

  6. Wong CT, Saha N. Changes in serum proteins (albumin, immunoglobulins and acute phase proteins) in pulmonary tuberculosis during therapy. Tubercle 1990; 71: 193–7

    PubMed  CAS  Google Scholar 

  7. Hawkins JE. Drug susceptibility testing. In Kubica GP, Wayne LG, editors. The mycobacteria. A sourcebook. Part A. New York: Marcel Dekker Inc., 1984: 177–93

    Google Scholar 

  8. Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990b; 71: 241–5

    PubMed  CAS  Google Scholar 

  9. Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64: 38–40

    PubMed  CAS  Google Scholar 

  10. Speight TM, editor. Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics. 3rd ed. Auckland: ADIS Press, 1987

    Google Scholar 

  11. Mandel GL, Sande MA. Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. In: Goodman LS, Gilman AG, Gilman A, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. G & L ed. New York: MacMillan Publishing, 1980: 1162–221

    Google Scholar 

  12. Winstanley PA. The clinical pharmacology of anti-tuberculosis drugs. In Davies PDO, editor. Clinical Tuberculosis. London: Chapman & Hall, 1994: 129–40

    Google Scholar 

  13. Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, 1991

  14. Sunahara S, Urano M, Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science 1961; 134: 1530

    PubMed  CAS  Google Scholar 

  15. Des Prez R, Boone IU. Metabolism of C14 isoniazid in humans. Am Rev Respir Dis 1961; 84: 42–51

    Google Scholar 

  16. Radner DB. Toxicologic and pharmacologic aspects of rifampin. Chest 1973; 64: 213–6

    PubMed  CAS  Google Scholar 

  17. Cohn HD. Clinical studies with a new rifamycin derivative. J Clin Pharmacol 1969; 9: 118–25

    CAS  Google Scholar 

  18. Etzkorn ET, Aldarondo S, McAllister CK, et al. Medical therapy of mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis 1986; 134: 442–445

    PubMed  CAS  Google Scholar 

  19. Peets EA, Sweeney WM, Place VA, et al. The absorption, excretion and metabolic fate of ethambutol in man. Am Rev Respir Dis 1965; 91: 51–8

    PubMed  CAS  Google Scholar 

  20. Sande MA, Mandell GL. Antimicrobial agents. The aminoglycosides. In: Goodman LS, Gilman AG, Gilman A, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. G & L ed. New York: MacMillan Publishing, 1990: 1171–2

    Google Scholar 

  21. Hong Kong Chest Service/British Medical Research Council. Five year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339–42

    Google Scholar 

  22. Girling DJ. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. Tubercle 1984; 65: 1–4

    PubMed  CAS  Google Scholar 

  23. Bieder A, Brunei P, Mazeau L. Identification de trois nouveaux metabolites de l’ethionamide: Chromatographie, spectro-photometrie, Polarographie. Ann Pharmacol Fr 1966; 24: 493–500

    CAS  Google Scholar 

  24. Way EL, Smith PK, Howie DL, et al. The absorption, distribution, excretion and fate of para-amino-salicylic acid. J Pharmacol Exp Ther 1948; 93: 368–82

    PubMed  CAS  Google Scholar 

  25. Storey PB, Maclean RL. A current appraisal of cycloserine. Antibiot Med Clin Ther 1957; 4: 223–32

    CAS  Google Scholar 

  26. Holdiness MR. Clinical pharmacokinetics of antituberculous drugs. Clin Pharmacokinet 1982; 91: 511–44

    Google Scholar 

  27. Houston S, Fanning A. Current and potential treatment of tuberculosis. Drugs 1994; 48(5): 689–708

    PubMed  CAS  Google Scholar 

  28. Ji B, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of Sparfloxacin (AT-4140) against mycobacterium tuberculosis. Tubercle 1991; 72: 181–7

    PubMed  CAS  Google Scholar 

  29. Tomioka H, Sato K, Saito H. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria. Tubercle 1991; 72: 176–80

    PubMed  CAS  Google Scholar 

  30. Tsukamura M, Nakamura E, Yoshii S, et al. Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 352–6

    PubMed  CAS  Google Scholar 

  31. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992; 73: 59–67

    Google Scholar 

  32. Kohno S, Koga H, Kaku M, et al. Prospective comparative study of ofloxacin or ethambutol for treatment of pulmonary tuberculosis. Chest 1992; 102: 1815–8

    PubMed  CAS  Google Scholar 

  33. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1548–51

    Google Scholar 

  34. Flor S. Pharmacokinetics of ofloxacin. Am J Med 1989; 87 Suppl. 6C: 24S–30S

    PubMed  CAS  Google Scholar 

  35. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994; 75: 341–7

    PubMed  CAS  Google Scholar 

  36. Benson CA. Treatment of disseminated disease due to Mycobacterium avium complex in patients with AIDS. Clin Infec Dis 1994; 18 Suppl 3: S237–42

    Google Scholar 

  37. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981; 62: 95–102

    Google Scholar 

  38. Citron KM, Somner AR, Angel JH. Short duration chemotherapy in pulmonary tuberculosis. The occurrence of hepatitis in six month regimens containing pyrazinamide as well as rifampicin. Am Rev Respir Dis 1980; 121: 452

    Google Scholar 

  39. Tuberculosis Research Centre, Madras. Study of chemotherapy regimens of five and seven months duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983; 64: 73–91

    Google Scholar 

  40. Hong Kong Chest Service/British Research Council Study. A service programme with a six month intensive chemotherapy regimen in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Tubercle 1983; 64: 265–74

    Google Scholar 

  41. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months or pyrazinamide in 6-month three-times-weekly regimens for smear positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700–6

    Google Scholar 

  42. Zierski M, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis: a controlled clinical study. Tubercle 1980; 61: 41–9

    PubMed  CAS  Google Scholar 

  43. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 1982; 63: 89–98

    Google Scholar 

  44. East and Central African/British Medical Research Council Fifth Collaborative Study. First report: controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983; 64: 153–66

    Google Scholar 

  45. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986; 67(1): 5–15

    Google Scholar 

  46. Barnes PF, Chan LS, Wong SF. The course of fever during treatment of pulmonary tuberculosis. Tubercle 1987; 68: 255–60

    PubMed  CAS  Google Scholar 

  47. Pitts FW. Tuberculosis: prevention and therapy. In: Hook EW, Mandel GL, Gwaltney Jr JM, et al., editors. Current concepts of infectious diseases. New York: John Wiley and Sons, 1977: 181–94

    Google Scholar 

  48. Chan CHS, Chong YW, Sun AJM, et al. Cutaneous vasculitis associated with tuberculosis and its treatment. Tubercle 1990; 71: 297–300

    PubMed  CAS  Google Scholar 

  49. Miller AB, Nunn AJ, Robinson DF, et al. A second international co-operative investigation into thiacetazone side-effects. 2. Frequency and geographical distribution of side-effects. Bull World Health Organ 1972; 47: 211–27

    PubMed  CAS  Google Scholar 

  50. Mitchell JR, Lauterburg BH. Drug-induced liver injury. Hosp Pract Off Ed 1978; 13(9): 95–106

    CAS  Google Scholar 

  51. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 579–85

    Google Scholar 

  52. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. A controlled clinical trial of 3 and 5 monthly regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 1986; 134: 27–33

    Google Scholar 

  53. Steele MA, Burk RF, Des Prez RM. Toxic hepatitis with isoniazid and rifampicin. A meta-analysis. Chest 1991; 99: 465–71

    CAS  Google Scholar 

  54. Kumar A, Misra PK, Mehotra R, et al. Hepatoxicity of rifampicin and isoniazid. Is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143: 1350–2

    PubMed  CAS  Google Scholar 

  55. Sarma GR, Immanuel C, Kailasam S, et al. Rifampin induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampicin. Am Rev Respir Dis 1986; 133: 1072–5

    PubMed  CAS  Google Scholar 

  56. Jenner PJ, Ellard GA. Isoniazid-related hepatoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70: 93–101

    PubMed  CAS  Google Scholar 

  57. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid - rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118: 461–6

    PubMed  CAS  Google Scholar 

  58. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator pheno-type in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129: 58–61

    PubMed  CAS  Google Scholar 

  59. Riska NV. Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc 1976; 51: 203–8

    PubMed  CAS  Google Scholar 

  60. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service co-operative surveillance study. Am Rev Respir Dis 1978; 117: 991–1001

    PubMed  CAS  Google Scholar 

  61. Black M, Mitchell JR, Zimmerman HJ. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302

    PubMed  CAS  Google Scholar 

  62. Dash LA, Comstock GW, Flynn JPG. Isoniazid-preventive therapy: retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039–44

    PubMed  CAS  Google Scholar 

  63. Bartelink AKM, Lenders JWM, van Herwaarden CLA, et al. Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy. Tubercle 1983; 64: 125–8

    PubMed  CAS  Google Scholar 

  64. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67: 99–108

    PubMed  CAS  Google Scholar 

  65. Rothfield NF, Bierer WF, Garfield JW. Isoniazid: induction of anti-nuclear antibodies. Ann Intern Med 1978; 88: 650–2

    PubMed  CAS  Google Scholar 

  66. Good AE, Green RA, Zarafonetis CJD. Rheumatic symptoms during tuberculosis therapy: a manifestation of isoniazid toxicity. Ann Intern Med 1965; 63: 800–7

    PubMed  CAS  Google Scholar 

  67. Snider DE, Caras GJ. Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494–7

    PubMed  Google Scholar 

  68. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 140: 575–6

    Google Scholar 

  69. Chemoprophylaxis for tuberculosis [editorial]. Tubercle 1981; 62: 69–72

    Google Scholar 

  70. Claiborne RA, Dutt AK. Isoniazid induced pure red cell aplasia. Am Rev Respir Dis 1985; 131: 947–9

    PubMed  CAS  Google Scholar 

  71. Glassroth JL, White MC, Snider Jr DE. An assessment of the possible association of isoniazid with human cancer deaths. Am Rev Respir Dis 1977; 116: 1065–74

    PubMed  CAS  Google Scholar 

  72. Uragoda CG. Histamine poisoning in tuberculous patients after ingestion of tuna fish. Am Rev Respir Dis 1980; 121: 157–9

    PubMed  CAS  Google Scholar 

  73. Uragoda CG, Kottegoda BG. Adverse reactions to isoniazid on ingestion of fish with a high histamine content. Tubercle 1977; 58: 83–9

    PubMed  CAS  Google Scholar 

  74. Uragoda CG, Lodha SC. Histamine intoxication in a tuberculous patient after ingestion of cheese. Tubercle 1979; 60: 59–61

    PubMed  CAS  Google Scholar 

  75. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61: 191–6

    PubMed  Google Scholar 

  76. Lauterberg BH, Vaishnav Y, Mitchell JR. In vivo assessment of glucothione synthesis. Clin Res 1979; 27: 235A

    Google Scholar 

  77. Sharma GS, Gupta PK, Jain NK, et al. Toxic psychosis to isoniazid and ethionamide in a patient with pulmonary tuberculosis. Tubercle 1979; 60: 171–2

    PubMed  CAS  Google Scholar 

  78. McCune R, Deuschle K, McDermott W. Delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberculosis Pul Dis 1957; 76: 1100–5

    CAS  Google Scholar 

  79. Motion S, Humphries MJ, Gabriel M. Severe ‘flu-like’ symptoms due to isoniazid: a report of three cases. Tubercle 1989; 70: 57–60

    PubMed  CAS  Google Scholar 

  80. Madan A, Jain NK, Sharma TN, et al. Attempted suicide following treatment with isoniazid. Tubercle 1989; 70: 147–9

    PubMed  CAS  Google Scholar 

  81. Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ 1979; 57: 45

    PubMed  CAS  Google Scholar 

  82. Grosset J, Leventis F. Adverse effects of rifampin. Rev Infect Dis 1983; 5: 440

    Google Scholar 

  83. Pujet JC, Homberg JC, Decroix G. Sensitivity to rifampicin: incidence, mechanism and prevention. BMJ 1974; 2: 415–8

    PubMed  CAS  Google Scholar 

  84. Riska NV, Mattson K. Systemic reacions to intermittent rifampicin. Bull Int Union Tuberc 1974; 49 Suppl. 1: 280–5

    PubMed  Google Scholar 

  85. Girling DJ. Adverse reactions to rifampicin in anti-tuberculosis regimens. J Antimicrob Chemother 1977; 3: 115–32

    PubMed  CAS  Google Scholar 

  86. Scheuer PJ, Summerfield JA, Lal S, et al. Rifampin hepatitis. Lancet 1974; 1:421–5

    PubMed  CAS  Google Scholar 

  87. Bansal V, Bennett D, Molnar Z. Prolonged renal failure after rifampicin. Am Rev Respir Dis 1977; 116: 137–40

    PubMed  CAS  Google Scholar 

  88. Warrington RJ, Hogg GR, Paraskevas F, et al. Insidious rifampin-associated renal failure with light-chain proteinuria. Arch Intern Med 1977; 137: 927–30

    PubMed  CAS  Google Scholar 

  89. Gupta S, Grieco MH, Siegel I. Suppression of t-lymphocyte rosettes by rifampin. Ann Intern Med 1975; 82: 484–8

    PubMed  CAS  Google Scholar 

  90. Humber DP, Nsanzumuhire H, Aluock JA, et al. Controlled double-blind study of the effect of rifampicin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts. Am Rev Respir Dis 1980; 122: 425–36

    PubMed  CAS  Google Scholar 

  91. Takasu N, Yamada T, Miura H, et al. Rifampicin induced early phase hyperglycaemia in humans. Am Rev Respir Dis 1982; 125: 23–7

    PubMed  CAS  Google Scholar 

  92. Shah SC, Sharma RK, Hemangini, et al. Rifampicin induced osteomalacia. Tubercle 1981; 62: 207–9

    PubMed  CAS  Google Scholar 

  93. Nessi R, Bonoldi GL, Redaelli B, et al. Acute renal failure after rifampicin: a case report and survey of the literature. Nephron 1976; 16(2): 148–59

    PubMed  CAS  Google Scholar 

  94. Cohn JR, Fye DL, Sills JM, et al. Rifampicin-induced renal failure. Tubercle 1985; 66: 289–93

    PubMed  CAS  Google Scholar 

  95. Kumar S, Mehta J, Trived H. Light chain proteinuria and reversible renal failure in rifampin treated patients with tuberculosis. Chest 1976; 70: 564–5

    PubMed  CAS  Google Scholar 

  96. Hirsch D, Bia F, Kashgarian M, et al. Rapidly progressive glomerulonephritis during antituberculous therapy. Am J Nephrol 1983; 3: 7

    PubMed  CAS  Google Scholar 

  97. Long MW, Snider Jr DE, Farer LS. US Public Health Service co-operative trial of three rifampicin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879–94

    PubMed  CAS  Google Scholar 

  98. Dutt AK, Moers D, Stead WW. Undesirable side effects of isoniazid and rifampicin in largely twice-weekly short course chemotherapy for tuberculosis. Am Rev Respir Dis 1983; 128: 419–24

    PubMed  CAS  Google Scholar 

  99. Place VA, Thomas JP. Clinical pharmacology of ethambutol. Am Rev Respir Dis 1963; 87: 901–4

    PubMed  CAS  Google Scholar 

  100. Chatterjee V. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 1986; 80: 288–91

    PubMed  CAS  Google Scholar 

  101. Tuberculosis Research Centre, Madras. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis: a controlled trial of four regimens. Tubercle 1981; 62: 13–29

    Google Scholar 

  102. Khanna PK, Gupta VP, Singh MP. Ethambutol-induced hyper-uricaemia. Tubercle 1984; 65: 195–9

    PubMed  CAS  Google Scholar 

  103. Wilson WR, Wilkowski CJ, Wright AJ, et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100: 816–23

    PubMed  CAS  Google Scholar 

  104. Federspil P. Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin. Arch Otolaryngol 1977; 217: 147

    CAS  Google Scholar 

  105. Sarkar SK, Purohit SD, Sharma TN, et al. Stevens-Johnson syndrome caused by streptomycin. Tubercle 1982; 63: 137–8

    PubMed  CAS  Google Scholar 

  106. Snider DE, Graczyk J, Bek E, et al. Supervised six months treatment of newly-diagnosed pulmonary tuberculosis using isoniazid, rifampicin and pyrazinamide, with and without streptomycin. Am Rev Respir Dis 1984; 130: 1010–94

    Google Scholar 

  107. McDermott W, Ormond L, Muschenheim C, et al. Pyrazinam-ide-isoniazid in tuberculosis. Am Rev Tuberc 1954; 69: 319–33

    PubMed  CAS  Google Scholar 

  108. Sarma GR, Acharyulu GS, Kannapiran M, et al. Role of rifampicin in arthralgia induced by pyrazinamide. Tubercle 1983; 64: 93–100

    PubMed  CAS  Google Scholar 

  109. Ellard GA, Haslam RM. Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. Tubercle 1976; 57: 97–103

    PubMed  CAS  Google Scholar 

  110. Jenner PJ, Ellard GA, Allan WGL, et al. Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. Tubercle 1981; 62: 175–179

    PubMed  CAS  Google Scholar 

  111. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle 1976; 57: 81–95

    Google Scholar 

  112. Horsfall PAL, Plummer J. Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. Tubercle 1979; 60: 13–24

    PubMed  CAS  Google Scholar 

  113. Fox W. The current status of short-course chemotherapy. Tubercle 1979; 60: 177–90

    Google Scholar 

  114. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59: 13–32

    PubMed  CAS  Google Scholar 

  115. Simon E, Veres E, Banki G. Changes in SGOT activity during treatment with ethionamide. Scand J Respir Dis 1969; 50: 314–22

    PubMed  CAS  Google Scholar 

  116. Hong YP, Kim SC, Chang SC, et al. Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions. Tubercle 1988; 69: 241–53

    PubMed  Google Scholar 

  117. Mehrotra ML, Gautam KD, Chaube CK. Shortest possible acceptable effective ambulatory chemotherapy in pulmonary tuberculosis: preliminary report 1. Am Rev Respir Dis 1981; 124: 239–44

    PubMed  CAS  Google Scholar 

  118. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337: 627–30

    PubMed  CAS  Google Scholar 

  119. Shafran SD, Deschenes J, Miller M, et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethambutol [letter]. N Engl J Med 1994; 330: 438–9

    PubMed  CAS  Google Scholar 

  120. Grange JM, Winstanley PA, Davies PDO. Clinically signficant drug interactions with antituberculosis agents. Drug Safety 1994; 11(4): 242–51

    PubMed  CAS  Google Scholar 

  121. Acocella G, Conti R. Interaction of rifampicin with other drugs. Tubercle 1980; 61: 171–7

    PubMed  CAS  Google Scholar 

  122. Powell-Jackson PR, Gray BJ, Heaton RW, et al. Adverse effect of rifampicin administration on steroid-dependant asthma. Am Rev Respir Dis 1983; 128: 307–10

    PubMed  CAS  Google Scholar 

  123. Prober CG. Effect of rifampicin on chloramphenicol levels. N Engl J Med 1985; 312: 788–9

    PubMed  CAS  Google Scholar 

  124. Rahn KH, Mooy J, Bohm R, et al. Reduction of bioavailability of verapamil by rifampicin. N Engl J Med 1985; 312: 920–1

    PubMed  CAS  Google Scholar 

  125. Engelhard D, Streetman HR, Marks MI. Interaction of ketoconazole with rifampicin and isoniazid. N Engl J Med 1984; 311: 1681–3

    PubMed  CAS  Google Scholar 

  126. Jane F, Bastus JB. Carbamazepine-isoniazid interaction and online information retrieved. N Engl J Med 1983; 308: 658

    PubMed  CAS  Google Scholar 

  127. Craven PC. Interaction of ketoconazole with rifampicin and isoniazid. N Engl J Med 1985; 312: 1061

    PubMed  CAS  Google Scholar 

  128. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice-versa. A double-drug interaction. N Engl J Med 1982; 307: 1325–7

    CAS  Google Scholar 

  129. Patel AM, Streeton J, editors. Tuberculosis in Australia and New Zealand into the 1990s. Canberra: Australian Government Publishing Service, 1990

    Google Scholar 

  130. Matz JM, Borish LC, Routes JM, et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Resp Crit Care Med 1994; 149: 815–7

    PubMed  CAS  Google Scholar 

  131. Krishnaswamy K. Diseases of a tropical environment. In: Speight TM, editor. Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics, 3rd ed. Auckland: ADIS Press, 1987: 1281

    Google Scholar 

  132. Rapp RS, Campbell RW, Howell JC, et al. Isoniazid hepato-tox-icity in children. Am Rev Respir Dis 1978; 118: 794–6

    PubMed  CAS  Google Scholar 

  133. Dutt AK, Moers D, Stead WW. Smear negative, culture positive pulmonary tuberculosis: six month chemotherapy with isoniazid and rifamipcin. Am Rev Respir Dis 1990; 141: 1232–5

    PubMed  CAS  Google Scholar 

  134. Snider Jr DE, Layde PM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122: 65–79

    PubMed  Google Scholar 

  135. Potworowska M, Sianozecko E, Szreplodowicz R. Ethionamide treatment and pregnancy. Pol Med J 1966; 5: 1153–8

    Google Scholar 

  136. Hamadeh MA, Glassroth J. Tuberculosis and pregnancy. Chest 1992; 101: 1114–20

    PubMed  CAS  Google Scholar 

  137. Burka ER, Weaver Z, Marks P. Clinical spectrum of hemolytic anaemia associated with glucose-6-phosphate dehydrogenase deficiency. Ann Int Med 1966; 64: 817–25

    Google Scholar 

  138. Shneerson JM, Francis RS. Ethambutol in pregnancy-foetal exposure. Tubercle 1979; 60: 167–9

    PubMed  CAS  Google Scholar 

  139. Leff A, Herskowitz D, Gibert J, et al. Tuberculosis chemopro-phylaxis practices in metropolitan clinics. Am Rev Respir Dis 1979; 119: 161–70

    PubMed  CAS  Google Scholar 

  140. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Resp Crit Care Med 1994; 149: 1359–74

    Google Scholar 

  141. Rowe JW, Andres R, Jobin JD. Age-adjusted standards for creatinine clearance. Ann Intern Med 1976; 84(5): 567–9

    PubMed  CAS  Google Scholar 

  142. Nielson CP, Cusack B J, Vestal RE. Geriatric clinical pharmacology and therapeutics. In: Speight TM, editor. Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics, 3rd ed. Auckland: ADIS Press, 1987: 165

    Google Scholar 

  143. Gault MH, Cockcroft DW. Creatinine clearance and age [letter]. Lancet 1975; 2(1935): 612–3

    PubMed  CAS  Google Scholar 

  144. Chan SL. Chemotherapy of tuberculosis. In: Davies PDO, editor. Clinical Tuberculosis. London: Chapman & Hall Medical, 1994: 151–2

    Google Scholar 

  145. Cross FS, Long MW, Banner AS, et al. Rifampicin-isoniazid therapy of alcoholic and non-alcoholic tuberculous patients in the US Public Health Service co-operative therapy trial. Am Rev Respir Dis 1980; 122: 349–53

    PubMed  CAS  Google Scholar 

  146. Pilheu JA, DeSalvo MC, Koch OR, et al. An electron micoscopic study of the effects of pyrazinamide on the liver of tuberculosous patients. Bull Int Union Tuberc 1984; 59(3): 144–6

    Google Scholar 

  147. Ellard GA. The potential clinical significance of isoniazid ace-tylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 65: 211–27

    PubMed  CAS  Google Scholar 

  148. McGlynn KA, Lustbader ED, Sharrar RG, et al. Isoniazid prophylaxis in Hepatitis B carriers. Am Rev Respir Dis 1986; 134: 666–8

    PubMed  CAS  Google Scholar 

  149. Holdiness MR. A review of blood dyscrasias Induced by antituberculosis Drugs. Tubercle 1987; 68(4): 301–9

    PubMed  CAS  Google Scholar 

  150. Jain VK, Vardhan H, Prakash OM. Pyrazinamide-induced thrombocytopenia. Tubercle 1988; 69: 217–8

    PubMed  CAS  Google Scholar 

  151. Prasad R, Mukerji PK. Ethambutol-induced thrombocyto-paenia. Tubercle 1989; 70: 211–2

    PubMed  CAS  Google Scholar 

  152. Rabinovitz M, Pitlik SD, Halevy J, et al. Ethambutol-induced thrombocytopaenia. Chest 1982; 81: 765–6

    PubMed  CAS  Google Scholar 

  153. Ip M, Cheng KP, Cheung WC. Disseminated intravascular coagulopathy associated with rifampicin. Tubercle 1991; 72: 291–3

    PubMed  CAS  Google Scholar 

  154. Van Assendelft AHW. Renal failure and haemolysis caused by rifampicin. Tubercle 1986; 67: 234–5

    PubMed  Google Scholar 

  155. Eriki PP, Okwera A, Aisu T, et al. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis 1991; 143: 185–7

    PubMed  CAS  Google Scholar 

  156. Kavesh NG, Holzman RS, Seidlin M. The combined toxicity of azidothymidine and antimycobacterial agents. Am Rev Respir Dis 1989; 139: 1094–7

    PubMed  CAS  Google Scholar 

  157. Ramachandran P, Duraipandian M, Nazarajan M, et al. Three chemotherapy studies of tuberculous meningitis in children. Tubercle 1986; 67: 17–29

    PubMed  CAS  Google Scholar 

  158. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36–41

    Google Scholar 

  159. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive mantoux skin test. Am Rev Respir Dis 1990; 142: 848–53

    PubMed  CAS  Google Scholar 

  160. Sarma GR, Immanuel C, Ramachandran G, et al. Adrenocortical function in patients with pulmonary tuberculosis. Tubercle 1990; 71: 277–82

    PubMed  CAS  Google Scholar 

  161. Wilkins EGL, Hnizdo E, Cope E. Addisonian crisis induced by treatment with rifampicin. Tubercle 1989; 70: 69–73

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Queensland Health Chest Clinic, PO Box 232, North Quay, Brisbane, Queensland, 4002, Australia

    Anil M. Patel & James McKeon

Authors
  1. Anil M. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James McKeon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, A.M., McKeon, J. Avoidance and Management of Adverse Reactions to Antituberculosis Drugs. Drug-Safety 12, 1–25 (1995). https://doi.org/10.2165/00002018-199512010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199512010-00001

Keywords

Search

Navigation